CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (2014 - 2026)
CytomX Therapeutics (CTMX) posted Net Income towards Common Stockholders of -$20.67 million for Q2 2026, compared with -$154,000 a year earlier.
Powered by 
Analysis
CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Net Income towards Common Stockholders at CytomX Therapeutics was -$79.65 million; for FY2025, it came in at -$20.37 million.
- In prior years, CytomX Therapeutics' Net Income towards Common Stockholders was $31.87 million in FY2024, -$569,000 in FY2023, -$99.32 million in FY2022 and -$115.87 million in FY2021.
- Quarterly Net Income towards Common Stockholders has run from a low of -$34.82 million in Q4 2021 to a high of $23.53 million in Q1 2025 over five years.
- According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was -$18.25 million (Q1 2026), -$26.51 million (Q4 2025) and -$14.23 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | CytomX Therapeutics | 557.82 Mn | -399.84 Mn | - | -20.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.67 Mn |
| Mar 31, 2026 | -18.25 Mn |
| Dec 31, 2025 | -26.51 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Jun 30, 2025 | -154,000.00 |
| Mar 31, 2025 | 23.53 Mn |
| Dec 31, 2024 | 18.88 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | -6.53 Mn |
| Mar 31, 2024 | 13.79 Mn |
| Dec 31, 2023 | 837,000.00 |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -3.31 Mn |
| Dec 31, 2022 | -8.78 Mn |
| Sep 30, 2022 | -29.06 Mn |
| Jun 30, 2022 | -29.50 Mn |
| Mar 31, 2022 | -31.98 Mn |
| Dec 31, 2021 | -34.82 Mn |
| Sep 30, 2021 | -30.98 Mn |
API Access
CytomX Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CTMX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "CTMX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CTMX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();